From Guesswork to Predictive Precision: Optimize Your Asset ROI.
Transform uncertainty into competitive advantage. Leverage predictive foresight to navigate complex payer landscapes and secure the price your innovation deserves.
The Strategic Questions We Answer
Lead Indication Strategy
“In which indication can we secure the highest price and the most stable reimbursement path?”
HTA Resistance Mapping—Identify therapeutic areas with the lowest historical “No Added Benefit” rates in Germany (G-BA) and France (HAS).
Pricing Ceiling Analysis—Compare “Price Anchors” (cost of current Standard of Care) across indications to find the highest entry point.
Indication Sequencing—Simulate how the first indication’s price will set the “Price Anchor” for all future label expansions.
Pricing Corridor & Scenario Modeling
“What is the realistic pricing corridor, and how do clinical outcomes dictate the negotiation floor?”
Outcome-Price Correlation—Model the expected price corridor for each HTA rating (e.g., the exact price delta between “Minor” vs. “Considerable” added benefit).
Analog Benchmarking—Predictive analysis of realized net prices for similar products, adjusted for therapeutic value and market entry date.
The “Safe Zone”—Define the negotiation floor and ceiling by calculating historical acceptance ranges for comparable clinical profiles.
Evidence Maturity & Launch Timing
“Is our data mature enough to launch, or are we walking into a ‘No Added Benefit’ trap?”
Interim-Read-out Simulation—Predict if a “fast” submission based on interim data provides enough statistical power for G-BA/HAS acceptance.
Data Maturity Radar—Compare your trial’s current data maturity (e.g., % of OS events) against historical thresholds required for positive assessments.
HTA Outcome Prediction (The Core Engine)
“What is the statistical probability of achieving a specific ‘Added Benefit’ (DE) or ‘ASMR’ (FR) rating?”
Predictive Rating—Probabilistic forecasting of benefit categories based on your current efficacy and safety profile.
Driver Analysis—Pinpoint exactly which data points (e.g., HR for Morbidity vs. Quality of Life) will drive the final decision.
Sensitivity Modeling—Simulate how shifts in clinical outcomes (e.g., a wider confidence interval) impact the final price negotiation corridor.
Negotiation Strategy & Objection Radar
“Which ‘Red Flags’ will authorities raise, and how can we preemptively neutralize them?”
Objection Forecasting—Anticipation of the top 5 criticisms payers will raise (e.g., regarding ACT choice or subgroup definitions).
Rescue Strategy Mapping—Use historical precedents to find successful counter-arguments or post-hoc analyses that have salvaged past negotiations.
Secondary Endpoint Optimization—Identify “hidden value” in morbidity or QoL data that can compensate for a non-superior primary endpoint.
The “Risk Radar” Advantage
Stop Reacting. Start Anticipating.
Secure a decisive commercial advantage with a submission strategy optimized for speed, acceptance, and maximum value.
Acceptance
High Acceptance Rates
Predictive engine ensures high acceptance rates for proposed comparators.
Pricing
Optimized Pricing
Secure maximum benefit ratings with defensible, data-backed cost-effectiveness models.
Speed
Faster Approval
Reduce time-to-reimbursement by anticipating and resolving objections early.
Ready to predict your HTA outcome?
Flag comparator mismatches and evidence gaps early.
Predict My HTA Outcome